Alkhateeb, Hassan B. http://orcid.org/0000-0002-3609-8404
Mohty, Razan http://orcid.org/0000-0002-0189-8233
Greipp, Patricia
Bansal, Radhika http://orcid.org/0000-0003-0964-098X
Hathcock, Matthew
Rosenthal, Allison
Murthy, Hemant
Kharfan-Dabaja, Mohamed http://orcid.org/0000-0001-7394-5185
Bisneto Villasboas, Jose C. http://orcid.org/0000-0002-2907-0809
Bennani, Nora http://orcid.org/0000-0001-8358-5953
Ansell, Stephen M. http://orcid.org/0000-0003-1244-6758
Patnaik, Mrinal M. http://orcid.org/0000-0001-6998-662X
Litzow, Mark R. http://orcid.org/0000-0002-9816-6302
He, Rong http://orcid.org/0000-0001-6116-8163
Chen, Dong
Al-Kali, Aref http://orcid.org/0000-0002-0824-3715
Kenderian, Saad S. http://orcid.org/0000-0003-2767-3830
Lin, Yi http://orcid.org/0000-0002-1556-6416
Shah, Mithun Vinod http://orcid.org/0000-0002-5359-336X
Funding for this research was provided by:
Fraternal Order of Eagles
Paul Calabresi Program in Clinical/Translational Research at Mayo Clinic
Article History
Received: 30 April 2022
Revised: 6 July 2022
Accepted: 12 July 2022
First Online: 26 July 2022
Competing interests
: AA-K—Research support to institution: Novartis, Astex. MMP—Membership on an entity’s Board of Directors or advisory committees (Stemline Therapeutics) and Research funding (Kura Oncology). PG—Membership on an entity’s advisory board (AbbVie) Kharfan-Dabaja- Consultancy for Daiichi Sankyo. SSK—Patents and Royalties: Novartis, Humanigen, MustangBio, and Mettaforge; Research funding: Novartis, Kite/Gilead, Juno/BMS, Lentigen, Humanigen, Tolero, Sunesis/Viracta, MorphoSys, and Leahlabs; Scientific Advisory Boards: Novartis, Kite/Gilead, Juno/BMS, Humanigen; DSMB: Humanigen; Consultancy: Novartis, Torque, and Calibr.